Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharma company advancing cancer therapeutics, will participate in the H.C. Wainwright 27th ...

Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright ...

Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharma company developing cancer therapies, announced favorable interim safety results from ...

Kairos Pharma reported strong safety results from a Phase 2 trial of ENV-105 in mCRPC, with no serious toxicities seen in the ...

Kairos Pharma shares were higher as the company reported positive safety results from a clinical trial of ENV-105, or carotuximab, in patients with metastatic castration-resistant prostate cancer.

Wells Fargo posted adjusted earnings of $1.54 per share, beating market estimates of $1.40 per share. Wells Fargo reported a net interest income of $11.71 billion on Tuesday, down ...

Kairos Pharma Ltd (NYSE:KAPA) saw its stock jump 165% following the announcement of encouraging safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients battling metastatic ...

Investing.com -- Kairos Pharma Ltd (NYSE: KAPA) stock surged 165% after the clinical-stage biopharmaceutical company reported positive safety results from its ongoing Phase 2 clinical trial of ENV-105 ...

Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 ...

Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical On ...

LOS ANGELES, April 24, 2025--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, today provides a letter to stockholders from CEO John Yu, M.D.: ...